Abstract Number: 1180 • 2013 ACR/ARHP Annual Meeting
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
Background/Purpose: To describe the trends of epidemiology of gout and patterns of urate-lowering treatment in the UK general population from 1997-2012. Methods: We used the…Abstract Number: 405 • 2013 ACR/ARHP Annual Meeting
Gout and RA: Not Such a Rare Coexistence After All
Background/Purpose: According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been…Abstract Number: 1993 • 2013 ACR/ARHP Annual Meeting
Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Background/Purpose: To examine geographic variations of gout prevalence, incidence and management in the United Kingdom. Methods: We used the Clinical Practice Research Data-link (CPRD) to…Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…Abstract Number: 212 • 2013 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Background/Purpose: Dual-energy computed tomography (DECT) is an advanced imaging method with potential for monitoring urate deposition in patients with gout. The aim of this prospective…Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…Abstract Number: 213 • 2013 ACR/ARHP Annual Meeting
Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
Background/Purpose: Digital tomosynthesis is a recently developed imaging method in which multiple projected images obtained at different angles are collected with a digital detector. These…Abstract Number: 2001 • 2013 ACR/ARHP Annual Meeting
Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the…Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…Abstract Number: 180 • 2013 ACR/ARHP Annual Meeting
Familial Aggregation Of Female Premenopausal Gout –Monogenic, Polygenic Or Clinical Coincidence?
Background/Purpose: Primary gout is a multifactorial disease, in which genetic background and environmental factors interact with each other. Genetic predisposition is particularly prominent in those…Abstract Number: 2007 • 2013 ACR/ARHP Annual Meeting
Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Background/Purpose: Gout flares are the most common manifestation of gout. Gout flares are not well documented by diagnosis codes and are not adequately captured when…Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…Abstract Number: 1984 • 2013 ACR/ARHP Annual Meeting
Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout
Background/Purpose: Gout is a debilitating, chronic disease that requires ongoing treatment and effective self-management. Successful gout treatment depends on multiple factors, including educational attainment. Adequate…Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 49
- Next Page »
